Stock Analysis on Net
Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

Common-Size Income Statement
Quarterly Data

Merck & Co. Inc., common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Sales 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost of sales -26.74 -26.71 -26.76 -27.10 -28.06 -26.30 -28.89 -33.83 -28.64 -26.23 -27.22 -30.10 -44.21 -27.73 -29.06 -27.47 -30.92 -32.19 -28.92 -28.22
Gross profit 73.26% 73.29% 73.24% 72.90% 71.94% 73.70% 71.11% 66.17% 71.36% 73.77% 72.78% 69.90% 55.79% 72.27% 70.94% 72.53% 69.08% 67.81% 71.08% 71.78%
Selling, general and administrative -19.16 -15.78 -17.97 -17.11 -19.43 -16.85 -17.21 -14.61 -20.93 -17.76 -20.01 -20.58 -24.65 -19.52 -21.87 -21.19 -24.34 -20.88 -23.06 -22.42
Research and development -65.80 -20.72 -88.60 -29.52 -27.30 -29.41 -19.17 -16.20 -22.68 -18.59 -37.90 -22.70 -46.64 -27.01 -19.53 -18.32 -21.47 -25.84 -18.61 -17.85
Restructuring costs -1.74 -0.79 -1.00 -0.46 -0.35 -0.63 -0.97 -0.33 -1.29 -0.81 -0.72 -2.79 -2.47 -0.91 -0.76 -0.60 -1.63 -1.87 -0.50 -1.41
Operating income (loss) -13.44% 36.00% -34.34% 25.81% 24.87% 26.82% 33.75% 35.02% 26.45% 36.61% 14.16% 23.83% -17.97% 24.83% 28.78% 32.42% 21.63% 19.21% 28.90% 30.09%
Other income (expense), net -0.54 -0.79 -1.14 -0.61 0.54 -2.87 -3.00 -4.45 2.46 3.42 0.90 4.28 2.04 2.49 3.59 -0.59 1.89 -0.28 -1.19 -1.74
Income (loss) from continuing operations before taxes -13.98% 35.21% -35.48% 25.20% 25.40% 23.95% 30.75% 30.57% 28.91% 40.03% 15.06% 28.11% -15.93% 27.31% 32.37% 31.83% 23.52% 18.93% 27.71% 28.36%
Income tax provision from continuing operations 5.60 -5.45 -4.24 -5.69 -3.59 -2.21 -3.69 -3.48 -0.63 -5.28 -4.41 -2.24 -0.78 -3.85 -4.68 -5.13 -3.60 -3.55 -5.23 -1.90
Net income (loss) from continuing operations -8.38% 29.76% -39.72% 19.50% 21.81% 21.75% 27.06% 27.09% 28.28% 34.75% 10.65% 25.87% -16.72% 23.46% 27.69% 26.70% 19.92% 15.38% 22.48% 26.46%
Income from discontinued operations, net of taxes 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.46 0.00 2.91 4.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net income (loss) -8.38% 29.76% -39.72% 19.50% 21.81% 21.75% 27.06% 27.09% 27.82% 34.75% 13.56% 29.95% -16.72% 23.46% 27.69% 26.70% 19.92% 15.38% 22.48% 26.46%
Net (income) loss attributable to noncontrolling interests 0.00 -0.03 -0.02 -0.03 0.00 -0.03 -0.03 0.02 -0.03 -0.03 -0.01 -0.04 -0.02 -0.03 -0.07 0.00 -0.06 -0.05 0.22 0.49
Net income (loss) attributable to Merck & Co., Inc. -8.38% 29.73% -39.74% 19.47% 21.81% 21.71% 27.03% 27.11% 27.79% 34.72% 13.55% 29.91% -16.74% 23.43% 27.61% 26.70% 19.86% 15.33% 22.70% 26.95%

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Income statement item Description The company
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. Merck & Co. Inc. operating income (loss) as a percentage of sales increased from Q2 2023 to Q3 2023 but then slightly decreased from Q3 2023 to Q4 2023 not reaching Q2 2023 level.
Income (loss) from continuing operations before taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Merck & Co. Inc. income (loss) from continuing operations before taxes as a percentage of sales increased from Q2 2023 to Q3 2023 but then slightly decreased from Q3 2023 to Q4 2023 not reaching Q2 2023 level.
Net income (loss) attributable to Merck & Co., Inc. The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Merck & Co. Inc. net income (loss) attributable to Merck & Co., Inc. as a percentage of sales increased from Q2 2023 to Q3 2023 but then slightly decreased from Q3 2023 to Q4 2023 not reaching Q2 2023 level.